Treatment for Chronic Hepatitis C: FDA-approved Therapies
THE SAFETY AND EFFICACY OF VIRAMIDINE® PLUS PEGYLATED INTERFERON ALFA-2B VERSUS RIBAVIRIN PLUS PEGYLATED INTERFERON ALFA-2B IN THERAPY-NAÏVE PATIENTS INFECTED WITH HCV: PHASE 3 RESULTS Y Benhamou. Abstract 751.PEGINTERFERON ALFA-2A (PEGASYS) PLUS RIBAVIRIN (COPEGUS) FOR 16 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3. FINAL RESULTS OF THE ACCELERATE TRIAL M L Shiffman. Abstract 734.
Final Results of the REPEAT and ACCELERATE Trials of Peginterferon Alfa-2a (Pegasys)Plus Copegus (Ribavirin)
SUSTAINED VIROLOGIC RESPONSE (SVR) TO INTERFERON-ALFA-2B+/- RIBAVIRIN THERAPY AT 6 MONTHS RELIABLY PREDICTS LONG-TERM CLEARANCE OF HCV AT 5-YEAR FOLLOW UP J G McHutchison. Abstract 744.MULTICENTER RANDOMIZED TRIAL OF HCV TREATMENT WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN LIVER TRANSPLANT PATIENTS WITH ESTABLISHED RECURRENT HEPATITIS C: INTERIM ANALYSIS C Duvoux. Abstract 1.NATURAL HISTORY AND OUTCOME OF ACUTE HEPATITIS C IN PATIENTS WITH END STAGE RENAL DISEASE S Kamal. Abstract 7 (Oral).DIFFERENCES IN TREATMENT OUTCOME TO ANTIVIRAL THERAPY BASED ON GENOTYPE AND VIRAL LOAD IN HEPATITIS C GENOTYPES 2 AND 3 IN THE WIN-R TRIAL R S Brown.
HEPATITIS C VIRUS (HCV)-SPECIFIC CD4+ AND CD8+ T CELL RESPONSES IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRINL Capa. Abstract 421.
